| Naslov: | Real-world testing practices, treatment patterns and clinical outcomes in patients from Central Eastern Europe with EGFR-mutated advanced non-small cell lung cancer : a retrospective chart review study (REFLECT) |
|---|
| Avtorji: | ID Janžič, Urška, Klinika Golnik (Avtor)
ID Turnšek, Nina, Onkološki inštitut (Avtor)
ID Dediu, Mircea (Avtor)
ID Shterev Donev, Ivan (Avtor)
ID Lupu, Roxana (Avtor)
ID Teodorescu, Gabriela (Avtor)
ID Ciuleanu, Tudor (Avtor)
ID Płużański, Adam (Avtor) |
|---|
| Datoteke: |  URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/1718-7729/29/8/460/pdf?version=1660898466
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
 OI - Onkološki inštitut Ljubljana
|
|---|
| Povzetek: | The targeted therapy with tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor mutation (EGFRm) in advanced non-small cell lung cancer (NSCLC) changed the treatment paradigm. REFLECT study (NCT04031898) explored EGFR/T790M testing and treatment patterns in EGFRm NSCLC patients receiving first- or second-generation (1G/2G) EGFR TKIs as front-line (1L) in eight countries. Pooled data from Central Eastern Europe (CEE) countries from this study (Bulgaria, Poland, Romania, Slovenia) are presented here. This physician-led chart review study was conducted in patients with confirmed-EGFRm NSCLC initiating 1L 1G/2G EGFR TKIs between 2015–2018. The CEE cohort included 389 patients receiving 1L erlotinib (37%), afatinib (34%), and gefitinib (29%). Overall, 320 (82%) patients discontinued 1L, and 298 (77%) progression events were registered. Median progression free survival on 1L TKIs was 14.0 (95% CI: 12.6–15.6) months. Median overall survival from 1L start was 26.6 (95% CI: 24.1–29.0) months. Attrition rate between 1L and next line was 30%. Among patients with 1L progression, 200 (67%) were tested for T790M and 58% were positive. This first CEE analysis of treatments and outcomes in EGFRm NSCLC patients highlights the importance of using the most efficacious therapies currently available in 1L to reduce attrition and improve patient outcomes. |
|---|
| Ključne besede: | lung neoplasms, non-small cell lung carcinoma, Eastern Europe, real-world study, REFLECT study, epidermal growth factor receptor, lung cancer |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Datum sprejetja članka: | 11.08.2022 |
|---|
| Datum objave: | 17.08.2022 |
|---|
| Kraj izida: | Švica |
|---|
| Založnik: | MDPI |
|---|
| Leto izida: | 2022 |
|---|
| Št. strani: | str. 5833-5845 |
|---|
| Številčenje: | Vol. 29, iss. 8 |
|---|
| PID: | 20.500.12556/DiRROS-15465  |
|---|
| UDK: | 616.2 |
|---|
| ISSN pri članku: | 1198-0052 |
|---|
| DOI: | 10.3390/curroncol29080460 |
|---|
| COBISS.SI-ID: | 119484931 |
|---|
| Avtorske pravice: | © 2022 by the authors |
|---|
| Opomba: | Soavtorica iz Slovenije: Nina Turnšek
|
|---|
| Datum objave v DiRROS: | 09.09.2022 |
|---|
| Število ogledov: | 879 |
|---|
| Število prenosov: | 400 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
